Non steady state and steady state PKS Bayesian forecasting and vancomycin pharmacokinetics in ICU adult patients

Therapeutic Drug Monitoring

Volumn 21, Issue 4, 1999, Pages 395-403

  Polard, Elisabeth ^a   Le Bouquin, Vincent ^b   Le Corre, Pascal ^a,b   Kérebel, Christine ^b   Trout, Hervé ^c   Feuillu, Alain ^b   Le Verge, Roger ^a,c   Mallédant, Yannick ^b  

^a UNIVERSITÉ DE RENNES 1   (France)

^b RENNES UNIVERSITY HOSPITAL   (France)

^c Service de Cardiologie   (France)

Author keywords

Adult ICU patients; Bayesian forecasting; Pharmacokinetics; Vancomycin

Indexed keywords

CREATININE; OPIATE; VANCOMYCIN;

ADULT; AGED; ARTICLE; ARTIFICIAL VENTILATION; BAYES THEOREM; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG RESEARCH; FEMALE; FORECASTING; HUMAN; INTENSIVE CARE UNIT; MALE; POPULATION; PRIORITY JOURNAL; STEADY STATE; TIME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BAYES THEOREM; FEMALE; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; VANCOMYCIN;

EID: 0032777512     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199908000-00003     Document Type: Article

References (33)

1. Leader WG, Chandler MH, Castiglia M. Pharmacokinetics optimisation of vancomycin therapy. Clin Pharmacokinet 1995;28: 327-42.
2. Matzke GR, Zhanel G, Guay D. Clinical pharmacokinetics of vancomycin. Clin Pharmacokinet 1986;11:257-82.
3. Rodvold KA, Zokufa HZ, Rotschafer JC. Routine monitoring of serum vancomycin concentrations: can waiting be justified? Clin Pharm 1987;6:655-8.
4. Fernandez de Gatta M, Calvo V, Hernandez JM, Caballero D, San Miguel JF, Dominguez-Gil A. Cost-effectiveness analysis of serum vancomycin concentration monitoring in patients with hematologic malignancies. Clin Pharmacol Ther 1996;60:332-40.
5. Freeman CD, Quintiliani R, Nightingale CH. Vancomycin therapeutic drug monitoring: is it necessary ? Ann Pharmacother 1993; 27:594-8.
6. Goldstein E, Bartholomew WR, Vickers MK, Parr T. Are serum levels of vancomycin useful in the first week of therapy ? Mo Med 1995;92:596-9.
7. MacGowan A, Lovering A, White L, Reeves D. Why monitor peak vancomycin concentrations? [letter] Lancet 1995;345:645.
8. Chang D, Liem L, Malogolowkin M. A prospective study of vancomycin pharmacokinetics and dosage requirements in pediatric cancer patients. Pediatr Infect Dis J 1994;13:969-74.
9. Chang D. Influence of malignancy on the pharmacokinetics of vancomycin in infants and children. Pediatr Infect Dis J 1995;14: 667-73.
10. Gous AG, Dance MD, Lipman J, Luyt DK, Mathivha R, Scribante J. Changes in vancomycin pharmacokinetics in critically ill infants. Anaesth Intensive Care 1995;23:678-82.
11. McDougal A, Ling EW, Levine M. Vancomycin pharmacokinetics and dosing in premature neonates. Ther Drug Monit 1995;17:319-26.
12. Rodvold KA, Gentry CA, Plank GS, Kraus DM, Nickel E, Gross JR. Bayesian forecasting of serum vancomycin concentrations in neonates and infants. Ther Drug Monit 1995;17:239-46.
13. Rodvold KA, Everett JA, Pryka RD, Kraus DM. Pharmacokinetics and administration regimens of vancomycin in neonates, infants and children, Clin Pharmacokinet 1997;33:32-51.
14. Seay RE, Brundage RC, Jensen PD, Schilling CG, Edgren BE. Population pharmacokinetics of vancomycin in neonates. Clin Pharmacol Ther 1994;56:169-75.
15. Balram C, Lim BL, Lee EJ, Wong SY, Ang B. Validity of bayesian forecasting programme in therapeutic drug monitoring of vancomycin in a surgical intensive care unit: a prospective evaluation. Ann Acad Med Singapore 1996;25:492-95.
16. Fernandez de Gatta M, Fruns I, Dominguez-Gil A. Individualizing vancomycin dosing regimens: an evaluation of two pharmacoki-netics dosing programs in critically ill patients. Pharmacotherapy 1994;14:196-201.
17. Rodvold KA, Blum RA, Fischer JH, et al. Vancomycin pharmacokinetics in patients with various degrees of renal function. Antimicrob Agents Chemother 1988;32:848-52.
18. Pryka RD, Rodvold KA, Garrison M, Rotschafer JC. Individualizing vancomycin dosage regimens : one-versus two compartment Bayesian models. Ther Drug Monit 1989;11:450-4.
19. Rodvold KA, Pryka RD, Garrison M, Rotschafer JC. Evaluation of two-compartment Bayesian forecasting program for predicting vancomycin concentrations. Ther Drug Monit 1989;11:269-75.
20. Boxenbaum HG, Riegelman S, Elashoff RM. Statistical estimations in pharmacokinetics. J Phannacokinet Biopharm 1974;2: 123-48.
21. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 1981;9:503-12.
22. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance [erratum]. J Phannacokinet Biophann 1982;10:229.
23. Brown N, Ho DH, Fong KL, et al. Effects of hepatic function on vancomycin clinical pharmacology. Antimicrob Agents Chemother 1983;23:603-9.
24. Rotschafer JC, Crossley K, Zaske DE, Mead K, Sawchuk RJ, Solem LD. Pharmacokinetics of vancomycin: observations in 28 patients and dosage recommendations. Antimicrob Agents Chemother 1982;22:391-4.
25. Marti R, Rosell M, Pou L, Garcia L, Pascual C. Influence of biochemical parameters of liver function on vancomycin pharmacokinetics. Pharmacol Toxicol 1996;79:55-9.
26. Power BM, Forbes AM, Vernon van Heerden P, Ilett KF. Pharmacokinetics of drugs used in critically ill adults. Clin Pharmacokinet 1998;34:25-56.
27. Tod M, Padoin M, Minozzi C, Cougnard J, Petitjean O. Population pharmacokinetic study of isepamicin with intensive care unit patients. Antimicrob Agents Chemother 1996;40:983-7.
28. Triginer C, Izquierdo I, Fernandez R, et al. Gentamicin volume of distribution in critically ill septic patients. Intensive Care Med 1990;16:303-6.
29. Van-Dalen R, Vree TB. Pharmacokinetics of antibiotics in critically ill patients. Intensive Care Med 1990;16(suppl 3):235-8.
30. Sun H, Maderazo EG, Krussel AR. Serum protein-binding characteristics of vancomycin. Antimicrob Agents Chemother 1993;37: 1132-6.
31. Triginer C, Izquierdo I, Fernandez R, et al. Changes in gentamicin pharmacokinetic profiles induced by mechanical ventilation. Eur J Clin Pharmacol 1991;40:297-302.
32. Rybak MJ, Albrecht LM, Herman JR, Warbasse LH, Svensson CK. Vancomycin pharmacokinetics in burn patients and intravenous drug abusers. Antimicrob Agents Chemother 1990;34:792-5.
33. Wu G, Furlanut M. Predictions of serum vancomycin concentrations by means of six different equations for calculation of creatinine clearance. Int J Clin Pharmacol Res 1997;17:1-10.